The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · see citing works

<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · see citing works

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · see citing works

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · see citing works

Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery

Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689 · see citing works

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525 · see citing works

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489 · see citing works

Cell Death

Danial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651 · see citing works

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,442 · see citing works

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090 · see citing works

The landscape of somatic copy-number alteration across human cancers

Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017 · see citing works

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

Druker, B. J., Tamura, S., Buchdunger, E., Ohno-Jones, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 3,618 · see citing works

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407 · see citing works

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381 · see citing works

Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells

Vaux, D., Cory, S., & Adams, J. (1988) · Nature · doi:10.1038/335440a0 · Cited by 3,355 · see citing works

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy

Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219 · see citing works

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058 · see citing works

Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713 · see citing works

Serine Phosphorylation of Death Agonist BAD in Response to Survival Factor Results in Binding to 14-3-3 Not BCL-XL

Zha, J., Harada, H., Yang, E., Jockel, J., & Korsmeyer, S. J. (1996) · Cell · doi:10.1016/s0092-8674(00)81382-3 · Cited by 2,578 · see citing works

PUMA, a Novel Proapoptotic Gene, Is Induced by p53

Nakano, K., & Vousden, K. H. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00214-3 · Cited by 2,315 · see citing works

Interleukin-3-Induced Phosphorylation of BAD Through the Protein Kinase Akt

del Peso, L., González‐García, M., Page, C., Herrera, R., & Núñez, G. (1997) · Science · doi:10.1126/science.278.5338.687 · Cited by 2,213 · see citing works

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992 · see citing works

Involvement of the bcl -2 Gene in Human Follicular Lymphoma

Tsujimoto, Y., Cossman, J., Jaffe, E. S., & Croce, C. M. (1985) · Science · doi:10.1126/science.3874430 · Cited by 1,787 · see citing works

Cloning of the Chromosome Breakpoint of Neoplastic B Cells with the t(14;18) Chromosome Translocation

Tsujimoto, Y., Finger, L. R., Yunis, J. J., Nowell̀, P. C., & Croce, C. M. (1984) · Science · doi:10.1126/science.6093263 · Cited by 1,769 · see citing works

Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. E. (2004) · Science · doi:10.1126/science.1101637 · Cited by 1,605 · see citing works

Proapoptotic Bcl-2 Relative Bim Required for Certain Apoptotic Responses, Leukocyte Homeostasis, and to Preclude Autoimmunity

Bouillet, P., Metcalf, D., Huang, D. C. S., Tarlinton, D. M., Kay, T. W. H., Köntgen, F., Adams, J. M., & Strasser, A. (1999) · Science · doi:10.1126/science.286.5445.1735 · Cited by 1,504 · see citing works

Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer

Shaw, A. T., Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311107 · Cited by 1,495 · see citing works

Bid, Bax, and Lipids Cooperate to Form Supramolecular Openings in the Outer Mitochondrial Membrane

Kuwana, T., Mackey, M. R., Perkins, G. A., Ellisman, M. H., Latterich, M., Schneiter, R., Green, D. R., & Newmeyer, D. D. (2002) · Cell · doi:10.1016/s0092-8674(02)01036-x · Cited by 1,480 · see citing works

The BCL-2 Family Reunion

Chipuk, J. E., Moldoveanu, T., Llambi, F., Parsons, M. J., & Green, D. R. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.01.025 · Cited by 1,432 · see citing works

p53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa

Villunger, A., Michalak, E. M., Coultas, L., Müllauer, F., Böck, G., Ausserlechner, M. J., Adams, J. M., & Strasser, A. (2003) · Science · doi:10.1126/science.1090072 · Cited by 1,327 · see citing works

Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members

Certo, M. V., Moore, V. D. G., Nishino, M., Wei, G., Korsmeyer, S. J., Armstrong, S. A., & Letai, A. G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.027 · Cited by 1,290 · see citing works

PUMA Induces the Rapid Apoptosis of Colorectal Cancer Cells

Yu, J., Zhang, L., Hwang, P. M., Kinzler, K. W., & Vogelstein, B. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00213-1 · Cited by 1,282 · see citing works

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized

van Delft, M. F., Wei, A. H., Mason, K. D., Vandenberg, C. J., Chen, L., Czabotar, P. E., Willis, S. N., Scott, C. L., Day, C. L., Cory, S., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.027 · Cited by 1,237 · see citing works

Proapoptotic Bak is sequestered by Mcl-1 and Bcl-x L , but not Bcl-2, until displaced by BH3-only proteinsPreprint

Willis, S. N., Chen, L., Dewson, G., Wei, A. H., Naik, E., Fletcher, J. I., Adams, J. M., & Huang, D. C. S. (2005) · Genes & Development · doi:10.1101/gad.1304105 · Cited by 1,236 · see citing works

bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation

McDonnell, T. J., Deane, N., Platt, F. M., Nunez, G., Jaeger, U., McKearn, J. P., & Korsmeyer, S. J. (1989) · Cell · doi:10.1016/0092-8674(89)90174-8 · Cited by 1,213 · see citing works

Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation

Cleary, M. L., Smith, S. D., & Sklar, J. (1986) · Cell · doi:10.1016/0092-8674(86)90362-4 · Cited by 1,212 · see citing works

BH3 Domains of BH3-Only Proteins Differentially Regulate Bax-Mediated Mitochondrial Membrane Permeabilization Both Directly and Indirectly

Kuwana, T., Bouchier-Hayes, L., Chipuk, J. E., Bonzon, C., Sullivan, B. A., Green, D. R., & Newmeyer, D. D. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.02.003 · Cited by 1,185 · see citing works

Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around Jh on chromosome 14 and near a transcriptional unit on 18

Bakhshi, A., Jensen, J. P., Goldman, P., Wright, J. J., McBride, O. W., Epstein, A. L., & Korsmeyer, S. J. (1985) · Cell · doi:10.1016/s0092-8674(85)80070-2 · Cited by 1,177 · see citing works

Induction of bcl-2 expression by epstein-barr virus latent membrane protein 1 protects infected B cells from programmed cell death

Henderson, S., Rowe, M., Gregory, C. D., Croom-Carter, D. S. G., Wang, F., Longnecker, R., Kieff, E. D., & Rickinson, A. B. (1991) · Cell · doi:10.1016/0092-8674(91)90007-l · Cited by 1,166 · see citing works

Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis

Rivlin, N., Brosh, R., Oren, M., & Rotter, V. (2011) · Genes &amp; Cancer · doi:10.1177/1947601911408889 · Cited by 1,033 · see citing works

Programmed Anuclear Cell Death Delimits Platelet Life Span

Mason, K. D., Carpinelli, M. R., Fletcher, J. I., Collinge, J. E., Hilton, A. A., Ellis, S., Kelly, P. N., Ekert, P. G., Metcalf, D., Roberts, A. W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.037 · Cited by 1,031 · see citing works

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

Konopleva, M. Y., Contractor, R., Tsao, T., Samudio, I. J., Ruvolo, P. P., Kitada, S., Deng, X., Zhai, D., Shi, Y.-X., Sneed, T. B., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.006 · Cited by 1,020 · see citing works

Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis

Yin, X.-M., Wang, K., Gross, A., Zhao, Y., Zinkel, S., Klocke, B., Roth, K. A., & Korsmeyer, S. J. (1999) · Nature · doi:10.1038/23730 · Cited by 1,004 · see citing works

Dysregulation of Apoptosis in Cancer

Reed, J. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2941 · Cited by 993 · see citing works

Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18.

Cleary, M. L., & Sklar, J. L. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.21.7439 · Cited by 955 · see citing works

Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2

Strasser, A., Harris, A. W., Bath, M. L., & Cory, S. (1990) · Nature · doi:10.1038/348331a0 · Cited by 905 · see citing works

Puma is an essential mediator of p53-dependent and -independent apoptotic pathways

Jeffers, J. R., Parganas, E., Lee, Y., Yang, C., Wang, J., Brennan, J. A., Maclean, K. H., Han, J., Chittenden, T., Ihle, J. N., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00244-7 · Cited by 880 · see citing works

Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18)

McDonnell, T. J., & Korsmeyer, S. J. (1991) · Nature · doi:10.1038/349254a0 · Cited by 877 · see citing works

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

Roberts, A. W., Seymour, J. F., Brown, J. R., Wierda, W. G., Kipps, T. J., Khaw, S. L., Carney, D. A., He, S., Huang, D. C. S., Xiong, H., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7898 · Cited by 833 · see citing works

Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7

Wertz, I. E., Kusam, S., Lam, C., Okamoto, T., Sandoval, W. N., Anderson, D. J., Helgason, E., Ernst, J. A., Eby, M., Liu, J., et al. (2011) · Nature · doi:10.1038/nature09779 · Cited by 784 · see citing works

Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

Pan, R. A., Hogdal, L. J., Benito, J. M., Bucci, D. M., Han, L., Borthakur, G. M., Cortes, J. E., DeAngelo, D. J., Debose, L., Mu, H. H., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0609 · Cited by 734 · see citing works

BAX activation is initiated at a novel interaction site

Gavathiotis, E., Suzuki, M., Davis, M. L., Pitter, K., Bird, G. H., Katz, S. G., Tu, H.-C., Kim, H., Cheng, E. H.-Y., Tjandra, N., et al. (2008) · Nature · doi:10.1038/nature07396 · Cited by 700 · see citing works

bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia

Hanada, M., Delia, D., Aiello, A., Stadtmauer, E. A., & Reed, J. (1993) · Blood · doi:10.1182/blood.v82.6.1820.1820 · Cited by 673 · see citing works

Use of Statins and the Risk of Death in Patients With Prostate Cancer

Yu, O. H. Y., Eberg, M., Benayoun, S., Aprikian, A. G., Batist, G., Suissa, S., & Azoulay, L. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.4757 · Cited by 661 · see citing works

Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis

Nguyen, M., Marcellus, R. C., Roulston, A., Watson, M., Serfass, L., Madiraju, S. R. M., Goulet, D., Viallet, J., Bélec, L., Billot, X., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709443104 · Cited by 658 · see citing works

SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction

Inuzuka, H., Shaik, S., Onoyama, I., Gao, D., Tseng, A., Maser, R. S., Zhai, B., Wan, L., Gutiérrez, A., Lau, A. W., et al. (2011) · Nature · doi:10.1038/nature09732 · Cited by 635 · see citing works

Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression

Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.-M., Yang-Yen, H.-F., Karras, J., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci9940 · Cited by 633 · see citing works

Bcl-xL Retrotranslocates Bax from the Mitochondria into the Cytosol

Edlich, F., Banerjee, S., Suzuki, M., Cleland, M. M., Arnoult, D., Wang, C., Neutzner, A., Tjandra, N., & Youle, R. J. (2011) · Cell · doi:10.1016/j.cell.2011.02.034 · Cited by 630 · see citing works

Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737

Moore, V. D. G., Brown, J. R., Certo, M. V., Love, T. M., Novina, C. D., & Letai, A. G. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28281 · Cited by 604 · see citing works

Stepwise Activation of BAX and BAK by tBID, BIM, and PUMA Initiates Mitochondrial Apoptosis

Kim, H., Tu, H.-C., Ren, D., Takeuchi, O., Jeffers, J. R., Zambetti, G. P., Hsieh, J. J.-D., & Cheng, E. H.-Y. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.09.030 · Cited by 600 · see citing works

Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers.

Krajewska, M., Krajewski, S., Epstein, J. I., Shabaik, A. S., Sauvageot, J., Song, K. B., Kitada, S., & Reed, J. C. (1996) · Europe PMC (PubMed Central) · Cited by 590 · see citing works

Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy

Chonghaile, T. N., Sarosiek, K. A., Vo, T.-T. T., Ryan, J. A., Tammareddi, A., Moore, V. D. G., Deng, J., Anderson, K. C., Richardson, P. G. G., Tai, Y., et al. (2011) · Science · doi:10.1126/science.1206727 · Cited by 588 · see citing works

Bax Crystal Structures Reveal How BH3 Domains Activate Bax and Nucleate Its Oligomerization to Induce Apoptosis

Czabotar, P. E., Westphal, D., Dewson, G., Ma, S., Hockings, C., Fairlie, W. D., Lee, E. F., Yao, S., Robin, A. Y., Smith, B. J., et al. (2013) · Cell · doi:10.1016/j.cell.2012.12.031 · Cited by 573 · see citing works

PUMA mediates the apoptotic response to p53 in colorectal cancer cells

Yu, J., Wang, Z., Kinzler, K. W., Vogelstein, B., & Zhang, L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2627984100 · Cited by 565 · see citing works

Membrane Binding by tBid Initiates an Ordered Series of Events Culminating in Membrane Permeabilization by Bax

Lovell, J. F., Billen, L. P., Bindner, S., Shamas‐Din, A., Fradin, C., Leber, B. F., & Andrews, D. W. (2008) · Cell · doi:10.1016/j.cell.2008.11.010 · Cited by 565 · see citing works

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

Rudin, C. M., Hann, C. L., Garon, E. B., de Oliveira, M. R., Bonomi, P., Camidge, D. R., Chu, Q. S.-C., Giaccone, G., Khaira, D. K., Ramalingam, S. S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3090 · Cited by 563 · see citing works

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

Ng, K. P., Hillmer, A. M., Chuah, C. T. H., Juan, W. C., Ko, T. K., Teo, A. S. M., Ariyaratne, P. N., Takahashi, N., Sawada, K., Fei, Y., et al. (2012) · Nature Medicine · doi:10.1038/nm.2713 · Cited by 557 · see citing works

Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancer

Catz, S. D., & Johnson, J. L. (2001) · Oncogene · doi:10.1038/sj.onc.1204926 · Cited by 538 · see citing works

BH3 Profiling Identifies Three Distinct Classes of Apoptotic Blocks to Predict Response to ABT-737 and Conventional Chemotherapeutic Agents

Deng, J., Carlson, N. E., Takeyama, K., Cin, P. D., Shipp, M. A., & Letai, A. G. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.001 · Cited by 513 · see citing works

Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance

Wei, G., Twomey, D., Lamb, J., Schlis, K. D., Agarwal, J., Stam, R. W., Opferman, J. T., Sallan, S. E., den Boer, M. L., Pieters, R., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.09.006 · Cited by 505 · see citing works

BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations

Costa, D. B., Halmos, B., Kumar, A., Schumer, S., Huberman, M. S., Boggon, T. J., Tenen, D. G., & Kobayashi, S. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040315 · Cited by 499 · see citing works

Bim is a suppressor of Myc-induced mouse B cell leukemia

Egle, A., Harris, A. W., Bouillet, P., & Cory, S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401471101 · Cited by 482 · see citing works

Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function

Luciano, F., Jacquel, A., Colosetti, P., Herrant, M., Cagnol, S., Pages, G., & Auberger, P. (2003) · Oncogene · doi:10.1038/sj.onc.1206792 · Cited by 477 · see citing works

BID, BIM, and PUMA Are Essential for Activation of the BAX- and BAK-Dependent Cell Death Program

Ren, D., Tu, H.-C., Kim, H., Wang, G. X., Bean, G. R., Takeuchi, O., Jeffers, J. R., Zambetti, G. P., Hsieh, J. J.-D., & Cheng, E. H. Y. (2010) · Science · doi:10.1126/science.1190217 · Cited by 475 · see citing works

Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E

Hsieh, A. C., Costa, M. D., Zollo, O., Davis, C. B., Feldman, M. E., Testa, J. R., Meyuhas, O., Shokat, K. M., & Ruggero, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.021 · Cited by 464 · see citing works

The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy

Kelly, P. N., & Strasser, A. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2011.17 · Cited by 453 · see citing works

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

Leverson, J. D., Zhang, H., Chen, J., Tahir, S. K., Phillips, D. C., Xue, J., Nimmer, P., Jin, S., Smith, M., Xiao, Y., et al. (2015) · Cell Death &amp; Disease · doi:10.1038/cddis.2014.561 · Cited by 440 · see citing works

Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells

Derenne, S., Monia, B. P., Dean, N. M., Taylor, J. K., Rapp, M.-J., Harousseau, J., Bataille, R., & Amiot, M. (2002) · Blood · doi:10.1182/blood.v100.1.194 · Cited by 429 · see citing works

BID regulation by p53 contributes to chemosensitivity

Sax, J. K., Fei, P., Murphy, M. E., Bernhard, E., Korsmeyer, S. J., & El-Deiry, W. S. (2002) · Nature Cell Biology · doi:10.1038/ncb866 · Cited by 420 · see citing works

The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells

She, Q., Solit, D. B., Ye, Q., O'Reilly, K. E., Lobo, J. M., & Rosen, N. X. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.006 · Cited by 416 · see citing works

FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal

You, H., Pellegrini, M., Tsuchihara, K., Yamamoto, K., Häcker, G. A., Erlacher, M., Villunger, A., & Mak, T. W. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060353 · Cited by 413 · see citing works

Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy

Montero, J., Sarosiek, K. A., DeAngelo, J. D., Maertens, O., Ryan, J., Ercan, D., Piao, H., Horowitz, N. S., Berkowitz, R. S., Matulonis, U., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.042 · Cited by 378 · see citing works

Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models

Corcoran, R. B., Cheng, K. A., Hata, A. N., Faber, A. C., Ebi, H., Coffee, E. M., Greninger, P., Brown, R. D., Godfrey, J. T., Cohoon, T. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.007 · Cited by 377 · see citing works

Elevated Expression of the Apoptotic Regulator Mcl-1 at the Time of Leukemic Relapse

Kaufmann, S. H., Karp, J. E., Svingen, P. A., Krajewski, S., Burke, P. J., Gore, S. D., & Reed, J. C. (1998) · Blood · doi:10.1182/blood.v91.3.991.991_991_1000 · Cited by 368 · see citing works

Myeloid cell factor–1 is a critical survival factor for multiple myeloma

Zhang, B., Gojo, I., & Fenton, R. G. (2002) · Blood · doi:10.1182/blood.v99.6.1885 · Cited by 368 · see citing works

Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML

Vo, T.-T. T., Ryan, J. A., Carrasco, R. D., Neuberg, D. S., Rossi, D. J., Stone, R. M., DeAngelo, D. J., Frattini, M. G., & Letai, A. G. (2012) · Cell · doi:10.1016/j.cell.2012.08.038 · Cited by 348 · see citing works

Gefitinib-Induced Killing of NSCLC Cell Lines Expressing Mutant EGFR Requires BIM and Can Be Enhanced by BH3 Mimetics

Cragg, M. S., Kuroda, J., Puthalakath, H., Huang, D. C. S., & Strasser, A. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040316 · Cited by 341 · see citing works

Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival

Wuillème‐Toumi, S., Robillard, N., Gomez‐Bougie, P., Moreau, P., Gouill, S. L., Avet‐Loiseau, H., Harousseau, J., Amiot, M., & Bataille, R. (2005) · Leukemia · doi:10.1038/sj.leu.2403784 · Cited by 337 · see citing works

Bim and Bad mediate imatinib-induced killing of Bcr/Abl + leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic

Kuroda, J., Puthalakath, H., Cragg, M. S., Kelly, P. N., Bouillet, P., Huang, D. C. S., Kimura, S. H., Ottmann, O. G., Druker, B. J., Villunger, A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606176103 · Cited by 336 · see citing works

Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas

Gong, Y., Somwar, R., Politi, K. A., Balak, M. N., Chmielecki, J., Jiang, X., & Pao, W. J. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040294 · Cited by 322 · see citing works

Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition

Faber, A. C., Li, D., Song, Y., Liang, M., Yeap, B. Y., Bronson, R. T., Lifshits, E., Zhao, C., Maira, S.-M., Garcı́a-Echeverrı́a, C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905056106 · Cited by 315 · see citing works

Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations

Mukohara, T., Engelman, J. A., Hanna, N. H., Yeap, B. Y., Kobayashi, S. S., Lindeman, N. I., Halmos, B., Pearlberg, J., Tsuchihashi, Z., Cantley, L. C., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji238 · Cited by 313 · see citing works

CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene.

Ohtani‐Fujita, N., Fujita, T., Aoike, A., Osifchin, N. E., Robbins, P. D., & Sakai, T. (1993) · PubMed · Cited by 311 · see citing works

BH3-Triggered Structural Reorganization Drives the Activation of Proapoptotic BAX

Gavathiotis, E., Reyna, D. E., Davis, M. L., Bird, G. H., & Walensky, L. D. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.10.019 · Cited by 310 · see citing works

Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM

Tagawa, H., Karnan, S., Suzuki, R., Matsuo, K., Zhang, X., Ota, A., Morishima, Y., Nakamura, S., & Seto, M. (2004) · Oncogene · doi:10.1038/sj.onc.1208300 · Cited by 307 · see citing works

Discovery of Potent Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods and Structure-Based Design

Friberg, A., Vigil, D., Zhao, B., Daniels, R. N., Burke, J. P., García-Barrantes, P. M., Camper, D. V., Chauder, B. A., Lee, T., Olejniczak, E. T., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301448p · Cited by 306 · see citing works

A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy

Placzek, W. J., Wei, J., Kitada, S., Zhai, D., Reed, J. C., & Pellecchia, M. (2010) · Cell Death and Disease · doi:10.1038/cddis.2010.18 · Cited by 296 · see citing works

Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells

Essafi, A., de Mattos, S. F., Hassen, Y., Soeiro, I., Mufti, G. J., Thomas, N. S. B., Medema, R. H., & Lam, E. W. ‐. (2005) · Oncogene · doi:10.1038/sj.onc.1208421 · Cited by 293 · see citing works

BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors

Faber, A. C., Corcoran, R. B., Ebi, H., Sequist, L. V., Waltman, B. A., Chung, E., Incio, J., Digumarthy, S. R., Pollack, S. F., Song, Y., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0106 · Cited by 283 · see citing works

Phase I study of obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia

O'Brien, S. M., Claxton, D. F., Crump, M., Faderl, S. H., Kipps, T. J., Keating, M. J., Viallet, J., & Cheson, B. D. (2008) · Blood · doi:10.1182/blood-2008-02-137943 · Cited by 274 · see citing works

FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD–specific STAT5 activation

Yoshimoto, G., Miyamoto, T., Jabbarzadeh‐Tabrizi, S., Iino, T., Rocnik, J. L., Kikushige, Y., Mori, Y., Shima, T., Iwasaki, H., Takenaka, K., et al. (2009) · Blood · doi:10.1182/blood-2008-12-196055 · Cited by 274 · see citing works

Bad -deficient mice develop diffuse large B cell lymphoma

Ranger, A. M., Zha, J., Harada, H., Datta, S. R., Danial, N. N., Gilmore, A. P., Kutok, J. L., Beau, M. M. L., Greenberg, M. E., & Korsmeyer, S. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533446100 · Cited by 263 · see citing works

BID Preferentially Activates BAK while BIM Preferentially Activates BAX, Affecting Chemotherapy Response

Sarosiek, K. A., Chi, X., Bachman, J. A., Sims, J. J., Montero, J., Patel, L., Flanagan, A., Andrews, D. W., Sorger, P. K., & Letai, A. G. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.08.048 · Cited by 247 · see citing works

‘Seed’ analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737

Lin, X., Morgan-Lappe, S. E., Huang, X., Li, L., Zakula, D., Vernetti, L. A., Fesik, S. W., & Shen, Y. (2006) · Oncogene · doi:10.1038/sj.onc.1210166 · Cited by 245 · see citing works

Bcl-2 Is a Prognostic Marker in Breast Cancer Independently of the Nottingham Prognostic Index

Callagy, G. M., Pharoah, P. D. P., Pinder, S. E., Hsu, F. D., Nielsen, T. O., Ragaz, J., Ellis, I. O., Huntsman, D. D., & Caldas, C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2719 · Cited by 237 · see citing works

The Impact of <i>EGFR</i> T790M Mutations and <i>BIM</i> mRNA Expression on Outcome in Patients with <i>EGFR</i> -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial

Costa, C., Molina, M. A., Drozdowskyj, A., Giménez-Capitán, A., Bertran-Alamillo, J., Karachaliou, N., Gervais, R., Massuti, B., Wei, J., Moran, T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2233 · Cited by 229 · see citing works

BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia

Moore, V. D. G., Schlis, K. D., Sallan, S. E., Armstrong, S. A., & Letai, A. G. (2007) · Blood · doi:10.1182/blood-2007-06-098012 · Cited by 222 · see citing works

Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells

Song, L., Coppola, D., Livingston, S., Cress, W. D., & Haura, E. B. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.3.1496 · Cited by 217 · see citing works

Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic

Cragg, M. S., Jansen, E. S., Cook, M., Harris, C., Strasser, A., & Scott, C. L. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35437 · Cited by 207 · see citing works

Myeloid Cell Leukemia-1 Inversely Correlates with Glycogen Synthase Kinase-3β Activity and Associates with Poor Prognosis in Human Breast Cancer

Ding, Q., He, X., Xia, W., Hsu, J.-M., Chen, C., Li, L., Lee, D., Yang, J.-Y., Xie, X., Liu, J.-C., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1788 · Cited by 195 · see citing works

Apoptosis Induction in Human Melanoma Cells by Inhibition of MEK Is Caspase-Independent and Mediated by the Bcl-2 Family Members PUMA, Bim, and Mcl-1

Wang, Y. F., Jiang, C. C., Avery‐Kiejda, K. A., Gillespie, S. K. H., Zhang, X. D., & Hersey, P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0665 · Cited by 194 · see citing works

20 years studying p53 functions in genetically engineered mice

Donehower, L. A., & Lozano, G. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2731 · Cited by 193 · see citing works

MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes

Zhou, P., Levy, N. B., Xie, H., Qian, L., Lee, C. G., Gascoyne, R. D., & Craig, R. W. (2001) · Blood · doi:10.1182/blood.v97.12.3902 · Cited by 188 · see citing works

The role of BH3-only protein Bim extends beyond inhibiting Bcl-2–like prosurvival proteins

Mérino, D., Giam, M., Hughes, P., Siggs, O. M., Heger, K., O’Reilly, L. A., Adams, J. M., Strasser, A., Lee, E. F., Fairlie, W. D., et al. (2009) · The Journal of Cell Biology · doi:10.1083/jcb.200905153 · Cited by 186 · see citing works

βTrCP- and Rsk1/2-Mediated Degradation of BimEL Inhibits Apoptosis

Dehan, E., Bassermann, F. C., Guardavaccaro, D., Vasiliver-Shamis, G., Cohen, M. S., Lowes, K. N., Dustin, M. L., Huang, D. C. S., Taunton, J., & Pagano, M. (2009) · Molecular Cell · doi:10.1016/j.molcel.2008.12.020 · Cited by 186 · see citing works

Small molecule Mcl-1 inhibitors for the treatment of cancer

Belmar, J., & Fesik, S. W. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.08.003 · Cited by 176 · see citing works

ERK1/2‐dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl‐1 and Bcl‐xL

Ewings, K. E., Hadfield‐Moorhouse, K., Wiggins, C. M., Wickenden, J. A., Balmanno, K., Gilley, R., Degenhardt, K., White, E., & Cook, S. J. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601723 · Cited by 176 · see citing works

Antiapoptotic BCL-2 is required for maintenance of a model leukemia

Letai, A. G., Sorcinelli, M. D., Beard, C., & Korsmeyer, S. J. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.07.011 · Cited by 174 · see citing works

BCL-2 in prostate cancer: A minireview

Catz, S. D., & Johnson, J. L. (2003) · APOPTOSIS · doi:10.1023/a:1021692801278 · Cited by 174 · see citing works

Effects of Erlotinib in <i>EGFR</i> Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib

Costa, D. B., Nguyen, K.-S. H., Cho, B. C., Sequist, L. V., Jackman, D. M., Riely, G. J., Yeap, B. Y., Halmos, B., Kim, J. H., Jänne, P. A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1455 · Cited by 171 · see citing works

Still embedded together binding to membranes regulates Bcl-2 protein interactions

Leber, B. F., Lin, J., & Andrews, D. W. (2010) · Oncogene · doi:10.1038/onc.2010.283 · Cited by 167 · see citing works

Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines

Zhang, H., Guttikonda, S. R., Roberts, L., Uziel, T., Semizarov, D., Elmore, S. W., Leverson, J. D., & Lam, L. T. (2010) · Oncogene · doi:10.1038/onc.2010.559 · Cited by 164 · see citing works

Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity

Bruncko, M., Wang, L., Sheppard, G. S., Phillips, D. C., Tahir, S. K., Xue, J., Erickson, S., Fidanze, S., Fry, E., Hasvold, L., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501258m · Cited by 164 · see citing works

Immunohistochemical Analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 Expression in Pancreatic Cancers

Miyamoto, Y., Hosotani, R., Wada, M., Lee, J.-U., Koshiba, T., Fujimoto, K., Tsuji, S., Nakajima, S., Doi, R., Kato, M., et al. (1999) · Oncology · doi:10.1159/000011933 · Cited by 159 · see citing works

Overexpression of Bcl-2 inhibits alveolar cell apoptosis during involution and accelerates c-myc-induced tumorigenesis of the mammary gland in transgenic mice

Jäger, R., Herzer, U., Schenkel, J., & Weiher, H. (1997) · Oncogene · doi:10.1038/sj.onc.1201353 · Cited by 159 · see citing works

Proapoptotic BH3-Only BCL-2 Family Protein BIM Connects Death Signaling from Epidermal Growth Factor Receptor Inhibition to the Mitochondrion

Deng, J., Shimamura, T., Perera, S. A., Carlson, N. E., Cai, D. D., Shapiro, G. I., Wong, K., & Letai, A. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1961 · Cited by 158 · see citing works

Direct activation of full-length proapoptotic BAK

Leshchiner, E. S., Braun, C. R., Bird, G. H., & Walensky, L. D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214313110 · Cited by 157 · see citing works

Roles of Bim in Apoptosis of Normal and Bcr-Abl-Expressing Hematopoietic Progenitors

Kuribara, R., Honda, H., Matsui, H., Shinjyo, T., Inukai, T., Sugita, K., Nakazawa, S., Hirai, H., Ozawa, K., & Inaba, T. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.14.6172-6183.2004 · Cited by 156 · see citing works

EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC Inhibition

Nakagawa, T., Takeuchi, S., Yamada, T., Ebi, H., Sano, T., Nanjo, S., Ishikawa, D., Sato, M., Hasegawa, Y., Sekido, Y., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3479 · Cited by 156 · see citing works

Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity.

Bhargava, V., Kell, D., van de Rijn, M., & Warnke, R. A. (1994) · PubMed Central · Cited by 155 · see citing works

Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer

Takezawa, K., Okamoto, I., Nishio, K., Janne, P. A., & Nakagawa, K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2798 · Cited by 141 · see citing works

TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in <i>BRAF-</i> Mutant Melanoma

Corcoran, R. B., Rothenberg, S. M., Hata, A. N., Faber, A. C., Piris, A., Nazarian, R. M., Brown, R. D., Godfrey, J. T., Winokur, D., Walsh, J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005753 · Cited by 140 · see citing works

Melanoma Proliferation and Chemoresistance Controlled by the DEK Oncogene

Khodadoust, M. S., Verhaegen, M. E., Kappes, F., Riveiro‐Falkenbach, E., Cigudosa, J. C., Kim, D. S. L., Chinnaiyan, A. M., Markovitz, D. M., & Soengas, M. S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1063 · Cited by 135 · see citing works

Growth- and tumor-promoting effects of deregulated BCL2 in human B-lymphoblastoid cells.

Núñez, G., Seto, M., Seremetis, S. V., Ferrero, D., Grignani, F., Korsmeyer, S. J., & Dalla‐Favera, R. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.12.4589 · Cited by 131 · see citing works

Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer

Faber, A. C., Farago, A. F., Costa, C., Dastur, A., Gomez-Caraballo, M., Robbins, R., Wagner, B. L., Rideout, W. M., Jakubik, C. T., Ham, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411848112 · Cited by 127 · see citing works

Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa

Inoue, S., Riley, J., Gant, T. W., Dyer, M. J. S., & Cohen, G. M. (2007) · Leukemia · doi:10.1038/sj.leu.2404760 · Cited by 124 · see citing works

mTOR Inhibition Specifically Sensitizes Colorectal Cancers with <i>KRAS</i> or <i>BRAF</i> Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1

Faber, A. C., Coffee, E. M., Costa, C., Dastur, A., Ebi, H., Hata, A. N., Yeo, A. T., Edelman, E. J., Song, Y., Tam, A. T., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0315 · Cited by 124 · see citing works

BI-97C1, an Optically Pure Apogossypol Derivative as Pan-Active Inhibitor of Antiapoptotic B-Cell Lymphoma/Leukemia-2 (Bcl-2) Family Proteins

Wei, J., Stebbins, J. L., Kitada, S., Dash, R., Placzek, W. J., Rega, M. F., Wu, B., Cellitti, J. F., Zhai, D., Yang, L., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1001265 · Cited by 123 · see citing works

PUMA and BIM Are Required for Oncogene Inactivation–Induced Apoptosis

Bean, G. R., Ganesan, Y. T., Dong, Y., Takeda, S., Liu, H., Chan, P. M., Huang, Y., Chodosh, L. A., Zambetti, G. P., Hsieh, J. J.-D., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2003483 · Cited by 123 · see citing works

Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia

Xiang, Z., Luo, H., Payton, J. E., Cain, J., Ley, T. J., Opferman, J. T., & Tomasson, M. H. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39964 · Cited by 120 · see citing works

Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.

Bachmann, P., Piazza, R., Janes, M. E., Wong, N., Davies, C., Mogavero, A., Bhadri, V., Szymanska, B., Geninson, G., Magistroni, V., et al. (2010) · Blood · doi:10.1182/blood-2010-05-284968 · Cited by 118 · see citing works

Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma

Richter, J. Á., Robles, E. F., Fresquet, V. J., Beltrán, E., Rullan, A., Agirre, X., Calasanz, M. J., Panizo, C., Richter, J. Á., Hernández‐Rivas, J. M., et al. (2010) · Blood · doi:10.1182/blood-2010-02-268003 · Cited by 113 · see citing works

The Role of BH3-Only Proteins in Tumor Cell Development, Signaling, and Treatment

Elkholi, R., Floros, K. V., & Chipuk, J. E. (2011) · Genes & Cancer · doi:10.1177/1947601911417177 · Cited by 109 · see citing works

Differences in the Mechanisms of Proapoptotic BH3 Proteins Binding to Bcl-XL and Bcl-2 Quantified in Live MCF-7 Cells

Aranovich, A., Liu, Q., Collins, T., Geng, F., Dixit, S., Leber, B. F., & Andrews, D. W. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.01.030 · Cited by 103 · see citing works

Evaluation and critical assessment of putative MCL-1 inhibitors

Varadarajan, S., Vogler, M., Butterworth, M., Dinsdale, D. D., Walensky, L. D., & Cohen, G. M. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.79 · Cited by 101 · see citing works

A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer

Paik, P. K., Rudin, C. M., Pietanza, M. C., Brown, A. B., Rizvi, N. A., Takebe, N., Travis, W. D., James, L. P., Ginsberg, M. S., Juergens, R. A., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.05.005 · Cited by 98 · see citing works

MCL-1 expression in B-cell non-Hodgkin’s lymphomas

Cho‐Vega, J. H., Rassidakis, G. Z., Admirand, J. H., Oyarzo, M. P., Ramalingam, P., Paraguya, A., McDonnell, T. J., Amin, H. M., & Medeiros, L. J. (2004) · Human Pathology · doi:10.1016/j.humpath.2004.04.018 · Cited by 97 · see citing works

PUMA expression is significantly reduced in human cutaneous melanomas

Karst, A. M., Dai, D. L., Martinka, M., & Li, G. (2004) · Oncogene · doi:10.1038/sj.onc.1208374 · Cited by 91 · see citing works

Low-Level Expression of Proapoptotic Bcl-2–Interacting Mediator in Leukemic Cells in Patients with Chronic Myeloid Leukemia: Role of BCR/ABL, Characterization of Underlying Signaling Pathways, and Reexpression by Novel Pharmacologic Compounds

Aichberger, K. J., Mayerhofer, M., Krauth, M., Vales, A., Kondo, R., Derdak, S. V., Pickl, W. F., Selzer, E., Deininger, M. W., Druker, B. J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0972 · Cited by 91 · see citing works

Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia

José‐Eneriz, E. S., Agirre, X., Jiménez‐Velasco, A., Cordeu, L., Martín, V., Arqueros, V., Gárate, L., Fresquet, V. J., Cervantes, F., Martinez-Climent, J. A., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.04.005 · Cited by 90 · see citing works

Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK

McCoy, F. P. G., Hurwitz, J. L., McTavish, N., Paul, I., Barnes, C., O’Hagan, B. M. G., Odrzywół, K. E., Murray, J. T., Longley, D. B., McKerr, G., et al. (2010) · Cell Death and Disease · doi:10.1038/cddis.2010.86 · Cited by 90 · see citing works

Phase II Study of Obatoclax Mesylate (GX15-070), a Small-Molecule BCL-2 Family Antagonist, for Patients With Myelofibrosis

Parikh, S. A., Kantarjian, H. M., Schimmer, A. D., Walsh, W., Asatiani, E., El‐Shami, K., Winton, E. F., & Verstovšek, S. (2010) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2010.n.059 · Cited by 89 · see citing works

The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non–small cell lung cancer

Zhao, M., Zhang, Y., Cai, W., Li, J., Zhou, F., Cheng, N., Ren, R., Zhao, C., Li, X., Ren, S., et al. (2014) · Cancer · doi:10.1002/cncr.28725 · Cited by 87 · see citing works

Fragment-based discovery of potent inhibitors of the anti-apoptotic MCL-1 protein

Petros, A. M., Swann, S. L., Song, D., Swinger, K. K., Park, C., Zhang, H., Wendt, M. D., Kunzer, A. R., Souers, A. J., & Sun, C. C. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.02.010 · Cited by 83 · see citing works

The Role of BRAF Mutation and p53 Inactivation during Transformation of a Subpopulation of Primary Human Melanocytes

Yu, H., McDaid, R., Lee, J., Possik, P. A., Li, L., Kumar, S. M., Elder, D. E., Belle, P. A. V., Gimotty, P. A., Guerra, M., et al. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.081057 · Cited by 79 · see citing works

Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models

Tan, N., Wong, M., Nannini, M., Hong, R., Lee, L. B., Price, S., Williams, K. R., Savy, P., Yue, P., Sampath, D., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0949 · Cited by 79 · see citing works

Mitogen-Activated Protein Kinase Inhibition Induces Translocation of Bmf to Promote Apoptosis in Melanoma

VanBrocklin, M. W., Verhaegen, M. E., Soengas, M. S., & Holmen, S. L. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3934 · Cited by 77 · see citing works

Gene Expression-Based Chemical Genomics Identifies Potential Therapeutic Drugs in Hepatocellular Carcinoma

Chen, M., Yang, W.-L. R., Lin, K., Liu, C.-H., Liu, Y.-W., Huang, K., Chang, P. M., Lai, J.-M., Hsu, C.-N., Chao, K., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027186 · Cited by 75 · see citing works

Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers

Hata, A. N., Yeo, A., Faber, A. C., Lifshits, E., Chen, Z., Cheng, K. A., Walton, Z., Sarosiek, K. A., Letai, A., Heist, R. S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3728 · Cited by 74 · see citing works

Clinical Significance of BIM Deletion Polymorphism in Non–Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation

Isobe, K., Hata, Y., Tochigi, N., Kaburaki, K., Kobayashi, H., Makino, T., Otsuka, H., Sato, F., Ishida, F., Kikuchi, N., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000125 · Cited by 69 · see citing works

Colorectal cancer cells with the BRAFV600E mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM

Wickenden, J. A., Jin, H., Johnson, M., Gillings, A. S., Newson, C., Austin, M. J., Chell, S. D., Balmanno, K., Pritchard, C. A., & Cook, S. J. (2008) · Oncogene · doi:10.1038/onc.2008.335 · Cited by 67 · see citing works

Apoptosis In Targeted Therapy Responses

Faber, A. C., Ebi, H., Costa, C., & Engelman, J. A. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00016-6 · Cited by 62 · see citing works

Pan-Mammalian Target of Rapamycin (mTOR) Inhibitor AZD8055 Primes Rhabdomyosarcoma Cells for ABT-737-induced Apoptosis by Down-regulating Mcl-1 Protein

Preuß, E., Hugle, M., Reimann, R., Schlecht, M., & Fulda, S. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.495986 · Cited by 62 · see citing works

ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete- response rate and durable disease control.

Seymour, J. F., Davids, M. S., Pagel, J. M., Kahl, B. S., Wierda, W. G., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Huang, D. C. S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.7015 · Cited by 58 · see citing works

The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance

Sale, M. J., & Cook, S. J. (2013) · Biochemical Journal · doi:10.1042/bj20121212 · Cited by 58 · see citing works

Fatal Acute Lymphoblastic Leukemia in Mice Transgenic for B Cell-Restricted bcl-xL and c- myc

Swanson, P. J., Kuslak, S. L., Wei, F., Tze, L. E., Gaffney, P. M., Selby, S. A., Hippen, K. L., Núñez, G., Sidman, C. L., & Behrens, T. W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.11.6684 · Cited by 55 · see citing works

Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAFV600E inhibition and can be targeted to reduce resistance

Serasinghe, M. N., Missert, D. J., Asciolla, J. J., Podgrabinska, S., Wieder, S. Y., Izadmehr, S., Belbin, G. M., Skobe, M., & Chipuk, J. E. (2014) · Oncogene · doi:10.1038/onc.2014.21 · Cited by 55 · see citing works

Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex

Piazza, R., Magistroni, V., Mogavero, A., Andreoni, F., Ambrogio, C., Chiarle, R., Mologni, L., Bachmann, P. S., Lock, R. B., Collini, P., et al. (2013) · Neoplasia · doi:10.1593/neo.121784 · Cited by 51 · see citing works

Sabutoclax (BI97C1) and BI112D1, Putative Inhibitors of MCL-1, Induce Mitochondrial Fragmentation Either Upstream of or Independent of Apoptosis

Varadarajan, S., Butterworth, M., Wei, J., Pellecchia, M., Dinsdale, D. D., & Cohen, G. M. (2013) · Neoplasia · doi:10.1593/neo.13230 · Cited by 49 · see citing works

Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics

Frederick, D. T., Fragomeni, R. A. S., Schalck, A. P., Ferreiro-Neira, I., Hoff, T., Cooper, Z. A., Haq, R., Panka, D. J., Kwong, L. N., Davies, M. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101286 · Cited by 49 · see citing works

Targeted overexpression of Bcl-XL in B-lymphoid cells results in lymphoproliferative disease and plasma cell malignancies

Linden, M. A., Kirchhof, N., Carlson, C. S., & Ness, B. V. (2003) · Blood · doi:10.1182/blood-2003-10-3399 · Cited by 47 · see citing works

Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma

Müller, A., Zang, C., Chumduri, C., Dörken, B., Daniel, P. T., & Scholz, C. W. (2013) · International Journal of Cancer · doi:10.1002/ijc.28206 · Cited by 47 · see citing works

Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small-Cell Lung Cancer

Lee, J., Lin, Y., Hsu, W., Chen, H., Chang, Y., Yu, C., Shih, J., Lin, C., Chen, K., Ho, C., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000238 · Cited by 44 · see citing works

Differences underlying EGFR and HER2 oncogene addiction

Faber, A. C., Wong, K., & Engelman, J. A. (2010) · Cell Cycle · doi:10.4161/cc.9.5.11096 · Cited by 41 · see citing works

Obatoclax Mesylate, a Pan–Bcl-2 Inhibitor, in Combination with Docetaxel in a Phase 1/2 Trial in Relapsed Non–Small-Cell Lung Cancer

Chiappori, A., Williams, C. C., Northfelt, D., Adams, J. W., Malik, S. M., Edelman, M. J., Rosen, P. J., Echo, D. A. V., Berger, M. S., & Haura, E. B. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000027 · Cited by 38 · see citing works

Mantle cell lymphoma in cyclin D1 transgenic mice with Bim-deficient B cells

Katz, S. G., LaBelle, J. L., Meng, H., Valeriano, R. P., Fisher, J. K., Sun, H. H., Rodig, S. J., Kleinstein, S. H., & Walensky, L. D. (2013) · Blood · doi:10.1182/blood-2013-04-499079 · Cited by 36 · see citing works

A single nucleotide polymorphism in cBIM is associated with a slower achievement of major molecular response in chronic myeloid leukaemia treated with imatinib

Augis, V., Airiau, K., Josselin, M., Turcq, B., Mahon, F.-X., & Belloc, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078582 · Cited by 35 · see citing works

Can the analysis of BH3-only protein knockout mice clarify the issue of ‘direct versus indirect’ activation of Bax and Bak?

Villunger, A., Labi, V., Bouillet, P., Adams, J. M., & Strasser, A. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2011.100 · Cited by 32 · see citing works

Targeting the Regulatory Machinery of BIM for Cancer Therapy

Harada, H., & Grant, S. (2012) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v22.i2.40 · Cited by 29 · see citing works

c-Cbl is not required for ERK1/2-dependent degradation of BimEL

Wiggins, C. M., Band, H., & Cook, S. J. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.08.008 · Cited by 25 · see citing works

The BCL 2L11 ( BIM ) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients

Katagiri, S., Umezu, T., Ohyashiki, J. H., & Ohyashiki, K. (2012) · British Journal of Haematology · doi:10.1111/bjh.12111 · Cited by 19 · see citing works

The C/EBP Homologous Protein (CHOP) Transcription Factor Functions in Endoplasmic Reticulum Stress-Induced Apoptosis and Microbial Infection

Hu, H., Tian, M., Ding, C., & Yu, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03083 · Cited by 1,140 · see citing works

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

Hata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985 · see citing works

Tumor biomarkers for diagnosis, prognosis and targeted therapy

Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 770 · see citing works

Precision medicine for cancer with next-generation functional diagnostics

Friedman, A. A., Letai, A., Fisher, D. E., & Flaherty, K. T. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4015 · Cited by 570 · see citing works

Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer

Liu, G., Pei, F., Yang, F., Li, L., Amin, A. D., Liu, S., Buchan, J. R., & Cho, W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020367 · Cited by 424 · see citing works

Cancer Stem Cell Quiescence and Plasticity as Major Challenges in Cancer Therapy

Chen, W., Dong, J., Haiech, J., Kilhoffer, M., & Zeniou, M. (2016) · Stem Cells International · doi:10.1155/2016/1740936 · Cited by 408 · see citing works

The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells

Nechiporuk, T., Kurtz, S. E., Nikolova, O. H., Liu, T., Jones, C. L., D’Alessandro, A., Culp‐Hill, R., d’Almeida, A., Joshi, S. K., Rosenberg, M. W., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0125 · Cited by 374 · see citing works

Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy

Pan, R., Ruvolo, V., Mu, H., Leverson, J. D., Nichols, G., Reed, J. C., Konopleva, M., & Andreeff, M. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.11.003 · Cited by 300 · see citing works

N6-methyladenosine methyltransferases: functions, regulation, and clinical potential

Huang, W., Chen, T.-Q., Fang, K., Zeng, Z., Ye, H., & Chen, Y.-Q. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01129-8 · Cited by 279 · see citing works

Molecular Targeted Therapies Elicit Concurrent Apoptotic and GSDME-Dependent Pyroptotic Tumor Cell Death

Lu, H., Zhang, S., Wu, J., Chen, M., Cai, M., Fu, Y., Li, W., Wang, J., Zhao, X., Yu, Z., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1478 · Cited by 270 · see citing works

Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening

Verissimo, C. S., Overmeer, R. M., Ponsioen, B., Drost, J., Mertens, S., Verlaan-Klink, I., Gerwen, B. V., van der Ven, M., Wetering, M. V. D., Egan, D. A., et al. (2016) · eLife · doi:10.7554/elife.18489 · Cited by 263 · see citing works

The Odyssey of Bioactive Compounds in Avocado (Persea americana) and Their Health Benefits

Bhuyan, D. J., Alsherbiny, M. A., Perera, Low, M., Basu, A., Devi, O. A., Barooah, M. S., Li, C. G., & Papoutsis, K. (2019) · Antioxidants · doi:10.3390/antiox8100426 · Cited by 260 · see citing works

Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer

Adachi, Y., Ito, K., Hayashi, Y., Kimura, R., Tan, T. Z., Yamaguchi, R., & Ebi, H. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2077 · Cited by 249 · see citing works

Role of the PI3K/AKT (mTOR and GSK3β) signalling pathway and photobiomodulation in diabetic wound healing

Jere, S. W., Houreld, N. N., & Abrahamse, H. (2019) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2019.03.001 · Cited by 252 · see citing works

Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer

Cabanos, H. F., & Hata, A. N. (2021) · Cancers · doi:10.3390/cancers13112666 · Cited by 189 · see citing works

Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis

Pan, R. A., Ryan, J. A., Pan, D., Wucherpfennig, K. W., & Letai, A. G. (2022) · Cell · doi:10.1016/j.cell.2022.03.030 · Cited by 199 · see citing works

Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer

López, A., Reyna, D. E., Gitego, N., Kopp, F., Zhou, H., Miranda-Román, M. A., Nordstrøm, L. U., Narayanagari, S.-R., Chi, P., Vilar, E., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28741-7 · Cited by 203 · see citing works

Mechanisms of Taxane Resistance

Maloney, S., Spring, C., Morejon-Lasso, L., & Prosperi, J. (2020) · Cancers · doi:10.3390/cancers12113323 · Cited by 198 · see citing works

STAT3 and apoptosis challenges in cancer

Fathi, N., Rashidi, G., Khodadadi, A., Shahi, S., & Sharifi, S. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.05.121 · Cited by 189 · see citing works

Mitochondrial quality control as a key determinant of cell survival

Sedlackova, L., & Korolchuk, V. I. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.12.012 · Cited by 186 · see citing works

Apoptosis in Cancer Biology and Therapy

Moyer, A. F., Tanaka, K., & Cheng, E. H. Y. (2025) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051222-115023 · Cited by 201 · see citing works

Fueling the Fire: Inflammatory Forms of Cell Death and Implications for Cancer Immunotherapy

Rosenbaum, S. R., Wilski, N. A., & Aplin, A. E. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0805 · Cited by 172 · see citing works

Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells

Carter, B. Z., Mak, P. Y., Mu, H. H., Zhou, H., Mak, D. H. F., Schober, W. D., Leverson, J. D., Zhang, B., Bhatia, R., Huang, X., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1180 · Cited by 170 · see citing works

Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis

Tanaka, K., Yu, H. A., Yang, S., Han, S., Selçuklu, S. D., Kim, K., Ramani, S., Ganesan, Y. T., Moyer, A. F., Sinha, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.006 · Cited by 165 · see citing works

Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia

Reyna, D. E., Garner, T. P., López, A., Kopp, F., Choudhary, G. S., Sridharan, A., Narayanagari, S.-R., Mitchell, K., Dong, B., Bartholdy, B., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.001 · Cited by 161 · see citing works

Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer

Mérino, D., Lok, S. W., Visvader, J. E., & Lindeman, G. J. (2015) · Oncogene · doi:10.1038/onc.2015.287 · Cited by 162 · see citing works

FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation

Tong, J., Tan, S., Zou, F., Yu, J., & Zhang, L. (2016) · Oncogene · doi:10.1038/onc.2016.247 · Cited by 160 · see citing works

Inhibitors of apoptosis: clinical implications in cancer

Mohamed, M. S., Bishr, M. K., Almutairi, F. M., & Ali, A. G. (2017) · APOPTOSIS · doi:10.1007/s10495-017-1429-4 · Cited by 159 · see citing works

Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer

D’Aguanno, S., & Bufalo, D. D. (2020) · Cells · doi:10.3390/cells9051287 · Cited by 152 · see citing works

Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors

Zhang, S., Zhang, M., Jing, Y., Yin, X., Ma, P., Zhang, Z., Wang, X., Di, W. J., & Zhuang, G. (2018) · Nature Communications · doi:10.1038/s41467-017-02693-9 · Cited by 146 · see citing works

Citrus Peel Flavonoids as Potential Cancer Prevention Agents

Koolaji, N., Shammugasamy, B., Schindeler, A., Dong, Q., Dehghani, F., & Valtchev, P. (2020) · Current Developments in Nutrition · doi:10.1093/cdn/nzaa025 · Cited by 142 · see citing works

Mechanisms of Resistance to Conventional Therapies for Osteosarcoma

Marchandet, L., Lallier, M., Charrier, C., Baud’huin, M., Ory, B., & Lamoureux, F. (2021) · Cancers · doi:10.3390/cancers13040683 · Cited by 137 · see citing works

Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial

Zelenetz, A. D., Salles, G., Mason, K. D., Casulo, C., Gouill, S. L., Sehn, L. H., Tilly, H., Cartron, G., Chamuleau, M. E. D., Goy, A. H., et al. (2019) · Blood · doi:10.1182/blood-2018-11-880526 · Cited by 136 · see citing works

Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination

Ham, J., Costa, C., Sano, R., Lochmann, T. L., Sennott, E. M., Patel, N. U., Dastur, A., Gomez‐Caraballo, M., Krytska, K., Hata, A. N., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.01.002 · Cited by 130 · see citing works

Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence

Darici, S., Alkhaldi, H., Horne, G. A., Jørgensen, H. G., Marmiroli, S., & Huang, X. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092934 · Cited by 130 · see citing works

Structural characterization of a novel neutral polysaccharide from Lentinus giganteus and its antitumor activity through inducing apoptosis

Tian, Y., Zhao, Y., Zeng, H., Zhang, Y., & Zheng, B. (2016) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2016.08.059 · Cited by 127 · see citing works

Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma

Khan, Z., Khan, A. A., Yadav, H., Prasad, G. B. K. S., & Bisen, P. S. (2017) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-017-0038-0 · Cited by 117 · see citing works

Failed Apoptosis Enhances Melanoma Cancer Cell Aggressiveness

Berthenet, K., Ferrer, C. C., Fanfone, D., Popgeorgiev, N., Neves, D., Bertolino, P., Gibert, B., Hernández‐Vargas, H., & Ichim, G. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107731 · Cited by 115 · see citing works

Cancer Stem Cells: From an Insight into the Basics to Recent Advances and Therapeutic Targeting

Bisht, S., Nigam, M., Kunjwal, S. S., Plygun, S., Mishra, A. P., & Sharifi‐Rad, J. (2022) · Stem Cells International · doi:10.1155/2022/9653244 · Cited by 110 · see citing works

Mfn2 Regulates High Glucose-Induced MAMs Dysfunction and Apoptosis in Podocytes via PERK Pathway

Cao, Y., Chen, Z., Hu, J., Feng, J., Zhu, Z., Fan, Y., Lin, Q., & Ding, G. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.769213 · Cited by 109 · see citing works

Fibrinogen Alpha Chain Knockout Promotes Tumor Growth and Metastasis through Integrin–AKT Signaling Pathway in Lung Cancer

Wang, M., Zhang, G., Zhang, Y., Cui, X., Wang, S., Gao, S., Wang, Y., Liu, Y., Bae, J. H., Yang, W., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-1033 · Cited by 108 · see citing works

Rising horizon in circumventing multidrug resistance in chemotherapy with nanotechnology

Choudhury, H., Pandey, M., Yin, T. H., Kaur, T., Jia, G. W., Tan, S. Q. L., Weijie, H., Yang, E. K. S., Keat, C. G., Bhattamisra, S. K., et al. (2019) · Materials Science and Engineering C · doi:10.1016/j.msec.2019.04.005 · Cited by 107 · see citing works

EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion–Positive Cholangiocarcinoma

Wu, Q., Zhen, Y., Shi, L., Vu, P., Greninger, P., Adil, R., Merritt, J., Egan, R., Wu, M.-J., Yin, X., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1168 · Cited by 104 · see citing works

Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma

Lochmann, T. L., Powell, K. M., Ham, J., Floros, K. V., Heisey, D. A. R., Kurupi, R., Calbert, M. L., Ghotra, M. S., Greninger, P., Dozmorov, M. G., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao4680 · Cited by 101 · see citing works

MYC and therapy resistance in cancer: risks and opportunities

Donati, G., & Amati, B. B. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13319 · Cited by 99 · see citing works

Emerging biomarkers and potential therapeutics of the BCL-2 protein family: the apoptotic and anti-apoptotic context

Saddam, M., Paul, S. K., Habib, M. A., Fahim, M. A., Mimi, A. A., Islam, S., Paul, B., & Helal, M. M. U. (2024) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-024-00485-7 · Cited by 108 · see citing works

Loss of exosomal miR-3188 in cancer-associated fibroblasts contributes to HNC progression

Wang, X., Qin, X., Yan, M., Shi, J., Xu, Q., Li, Z., Yang, W., Zhang, J., & Chen, W. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1144-9 · Cited by 98 · see citing works

Recent insights into apoptosis and toxic autophagy: The roles of MDA-7/IL-24, a multidimensional anti-cancer therapeutic

Emdad, L., Bhoopathi, P., Talukdar, S., Pradhan, A. K., Sarkar, D., Wang, X., Das, S. K., & Fisher, P. B. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.013 · Cited by 96 · see citing works

Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM

Song, K.-A., Niederst, M. J., Lochmann, T. L., Hata, A. N., Kitai, H., Ham, J., Floros, K. V., Hicks, M. A., Hu, H., Mulvey, H. E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1577 · Cited by 95 · see citing works

Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in <i>KRAS</i> -Mutant Non–Small Cell Lung Cancer

Nangia, V., Siddiqui, F. M., Caenepeel, S., Timonina, D., Bilton, S. J., Phan, N., Gomez-Caraballo, M., Archibald, H. L., Li, C., Fraser, C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0277 · Cited by 94 · see citing works

A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma

Ilyas, S. I., Yamada, D., Hirsova, P., Bronk, S. F., Werneburg, N. W., Krishnan, A., Salim, W., Zhang, L. N., Trushina, E. V., Truty, M. J., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.698472 · Cited by 94 · see citing works

Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas

Pham, L. V., Huang, S., Zhang, H., Zhang, J., Bell, T., Zhou, S., Pogue, E., Ding, Z., Lam, L. T., Westin, J. R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3004 · Cited by 94 · see citing works

Apoptotic Pathway as the Therapeutic Target for Anticancer Traditional Chinese Medicines

An, W., Lai, H., Zhang, Y., Liu, M., Lin, X., & Cao, S. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00758 · Cited by 93 · see citing works

Molecular Mechanisms Underlying Autophagy-Mediated Treatment Resistance in Cancer

Ho, C. J., & Gorski, S. M. (2019) · Cancers · doi:10.3390/cancers11111775 · Cited by 92 · see citing works

MiR-30a: A Novel Biomarker and Potential Therapeutic Target for Cancer

Jiang, L., Zhang, H.-D., & Tang, J.-H. (2018) · Journal of Oncology · doi:10.1155/2018/5167829 · Cited by 91 · see citing works

BH3-only protein BIM: An emerging target in chemotherapy

Shukla, S., Saxena, S., Singh, B. K., & Kakkar, P. (2017) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2017.09.002 · Cited by 87 · see citing works

Structure elucidation and antitumor activity of a water soluble polysaccharide from Hemicentrotus pulcherrimus

Jiang, Y., Shang, Z., Lv, X., Du, M., Li, M., Hou, G., Chen, J., Wang, C., & Zhao, F. (2022) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2022.119718 · Cited by 88 · see citing works

Targeting apoptosis in acute myeloid leukaemia

Cassier, P. A., Castets, M., Belhabri, A., & Vey, N. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.281 · Cited by 83 · see citing works

Anticancer effects of bifidobacteria on colon cancer cell lines

Faghfoori, Z., Faghfoori, M. H., Saber, A., Izadi, A., & Khosroushahi, A. Y. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01971-3 · Cited by 84 · see citing works

Individual-oocyte transcriptomic analysis shows that genotoxic chemotherapy depletes human primordial follicle reserve in vivo by triggering proapoptotic pathways without growth activation

Titus, S., Szymańska, K. J., Musul, B., Turan, V., Taylan, E., García-Milian, R., Mehta, S., & Oktay, K. (2021) · Scientific Reports · doi:10.1038/s41598-020-79643-x · Cited by 83 · see citing works

SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers

Jones, G. G., del Río, I. B., Sarı, S., Sekerim, A., Young, L. C., Hartig, N., Zubiaur, I. A., El-Bahrawy, M. A., Hynds, R. E., Lei, W., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10367-x · Cited by 77 · see citing works

KIF26B, a novel oncogene, promotes proliferation and metastasis by activating the VEGF pathway in gastric cancer

Zhang, H., Ma, R.-R., Wang, X.-J., Su, Z.-X., Chen, X.-L., Shi, D.-B., Guo, X.-Y., Liu, H.-T., & Gao, P. (2017) · Oncogene · doi:10.1038/onc.2017.163 · Cited by 77 · see citing works

The IGF-1 Signaling Pathway in Viral Infections

Józefiak, A., Larska, M., Pomorska‐Mól, M., & Ruszkowski, J. J. (2021) · Viruses · doi:10.3390/v13081488 · Cited by 76 · see citing works

Annurca apple polyphenol extract selectively kills MDA-MB-231 cells through ROS generation, sustained JNK activation and cell growth and survival inhibition

Martino, E., Vuoso, D. C., D’Angelo, S., Mele, L. L., D’Onofrio, N., Porcelli, M., & Cacciapuoti, G. (2019) · Scientific Reports · doi:10.1038/s41598-019-49631-x · Cited by 75 · see citing works

Mechanisms of Drug Resistance in Cancer: The Role of Extracellular Vesicles

Samuel, P., Fabbri, M., & Carter, D. R. F. (2017) · PROTEOMICS · doi:10.1002/pmic.201600375 · Cited by 74 · see citing works

Long non-coding RNA AC023115.3 suppresses chemoresistance of glioblastoma by reducing autophagy

Ma, B., Yuan, Z., Zhang, L., Lv, P., Yang, T., Gao, J., Pan, N., Wu, Q., Lou, J., Han, C., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.05.008 · Cited by 73 · see citing works

Natural Agents Targeting Mitochondria in Cancer

Mani, S., Swargiary, G., & Singh, K. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21196992 · Cited by 73 · see citing works

Structural characterization and antitumor activity of a novel Se-polysaccharide from selenium-enriched Cordyceps gunnii

Sun, H.-Q., Zhu, Z., Tang, Y., Ren, Y., Song, Q., Tang, Y., & Zhang, Y. (2018) · Food & Function · doi:10.1039/c8fo00027a · Cited by 72 · see citing works

MLL3 Induced by Luteolin Causes Apoptosis in Tamoxifen-Resistant Breast Cancer Cells through H3K4 Monomethylation and Suppression of the PI3K/AKT/mTOR Pathway

Wu, H., Liu, Y.-E., Hsu, K., Wang, Y., Chan, Y.-C., Chen, Y., & Chen, D. (2020) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x20500603 · Cited by 70 · see citing works

Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance

Kim, J., Shim, M. K., Yang, S., Moon, Y., Song, S., Choi, J., Kim, J., & Kim, K. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.10.065 · Cited by 70 · see citing works

Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia

Peirs, S., Frismantas, V., Matthijssens, F., Loocke, W. V., Pieters, T., Vandamme, N., Lintermans, B., Dobay, M. P., Berx, G., Poppe, B. G., et al. (2017) · Leukemia · doi:10.1038/leu.2017.10 · Cited by 70 · see citing works

RAC1 GTPase promotes the survival of breast cancer cells in response to hyper-fractionated radiation treatment

Hein, A. L., Post, C. M., Sheinin, Y. M., Lakshmanan, I., Natarajan, A., Enke, C. A., Batra, S. K., Ouellette, M. M., & Yan, Y. (2016) · Oncogene · doi:10.1038/onc.2016.163 · Cited by 69 · see citing works

Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition

Facchinetti, F., Rossi, G., Bria, E., Soria, J., Besse, B., Minari, R., Friboulet, L., & Tiseo, M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.02.010 · Cited by 69 · see citing works

Drug and apoptosis resistance in cancer stem cells (CSCs): A puzzle with many pieces

Safa, A. R. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.20 · Cited by 71 · see citing works

Antineoplastic activity of isoliquiritigenin, a chalcone compound, in androgen-independent human prostate cancer cells linked to G2/M cell cycle arrest and cell apoptosis

Zhang, B., Lai, Y., Li, Y., Shu, N., Wang, Z., Wang, Y., Li, Y., & Chen, Z. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.12.053 · Cited by 69 · see citing works

Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma

He, C., Liu, C., Wang, L., Sun, Y., Jiang, Y., & Hao, Y. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1347-1 · Cited by 66 · see citing works

Ellagic acid improves benign prostate hyperplasia by regulating androgen signaling and STAT3

Park, W. Y., Song, G., Park, J. Y., Ahn, K. S., Kwak, H. J., Park, J., Lee, J., & Um, J. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04995-3 · Cited by 67 · see citing works

Anti-tumor effect of evodiamine by inducing Akt-mediated apoptosis in hepatocellular carcinoma

Yang, F., Shi, L., Liang, T., Ji, L., Zhang, G., Shen, Y., Zhu, F., & Xu, L. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.02.017 · Cited by 67 · see citing works

A cold-water soluble polysaccharide isolated from Grifola frondosa induces the apoptosis of HepG2 cells through mitochondrial passway

Chen, P., Liu, H., Ji, H.-H., Sun, N., & Feng, Y. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.09.098 · Cited by 67 · see citing works

miR-30a-5p enhances paclitaxel sensitivity in non-small cell lung cancer through targeting BCL-2 expression

Xu, X., Jin, S., Ma, Y., Fan, Z., Yan, Z., Li, W., Song, Q., You, W., Lyu, Z., Song, Y., et al. (2017) · Journal of Molecular Medicine · doi:10.1007/s00109-017-1539-z · Cited by 66 · see citing works

Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR -Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target

Song, K.-A., Hosono, Y., Turner, C., Jacob, S., Lochmann, T. L., Murakami, Y., Patel, N. U., Ham, J., Hu, B., Powell, K. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0304 · Cited by 66 · see citing works

Cells, drugs and NMR

Siegal, G., & Selenko, P. (2019) · Journal of Magnetic Resonance · doi:10.1016/j.jmr.2019.07.018 · Cited by 65 · see citing works

Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies

Yan, X., Chen, D., Wang, Y., Guo, Y., Tong, C., Wei, J., Zhang, Y., Wu, Z., & Han, W. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00915-1 · Cited by 64 · see citing works

Orientin Induces G0/G1 Cell Cycle Arrest and Mitochondria Mediated Intrinsic Apoptosis in Human Colorectal Carcinoma HT29 Cells

Thangaraj, K., Balasubramanian, B., Park, S., Natesan, K., Liu, W., & Vaiyapuri, M. (2019) · Biomolecules · doi:10.3390/biom9090418 · Cited by 64 · see citing works

Glutathione Peroxidase 3 induced mitochondria-mediated apoptosis via AMPK /ERK1/2 pathway and resisted autophagy-related ferroptosis via AMPK/mTOR pathway in hyperplastic prostate

Li, Y., Zhou, Y., Liu, D., Wang, Z., Qiu, J., Zhang, J., Chen, P., Zeng, G., Guo, Y., Wang, X., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04432-9 · Cited by 65 · see citing works

Structural characterization of a low molecular weight polysaccharide from Grifola frondosa and its antitumor activity in H22 tumor-bearing mice

Ji, H., Yu, J., & Liu, A.-J. (2019) · Journal of Functional Foods · doi:10.1016/j.jff.2019.103472 · Cited by 61 · see citing works

Antitumor mechanisms of an exopolysaccharide from Lactobacillus fermentum on HT-29 cells and HT-29 tumor-bearing mice

Li, F., Jiao, X., Zhao, J., Liao, X., Wei, Y., & Li, Q. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.04.023 · Cited by 60 · see citing works

Bicyclic Helical Peptides as Dual Inhibitors Selective for Bcl2A1 and Mcl-1 Proteins

de Araujo, A. D., Lim, J., Wu, K., Xiang, Y., Good, A. C., Skerlj, R. T., & Fairlie, D. P. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00010 · Cited by 60 · see citing works

Purification of an acidic polysaccharide from Suaeda salsa plant and its anti-tumor activity by activating mitochondrial pathway in MCF-7 cells

Liu, X., Liu, F., Zhao, S., Guo, B., Ling, P., Han, G., & Cui, Z. (2019) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2019.03.059 · Cited by 60 · see citing works

The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism

Zaanan, A., Okamoto, K., Kawakami, H., Khazaie, K., Huang, S., & Sinicrope, F. A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.657833 · Cited by 59 · see citing works

Reactive oxygen species generation and mitochondrial dysfunction for the initiation of apoptotic cell death in human hepatocellular carcinoma HepG2 cells by a cyclic dipeptide Cyclo(-Pro-Tyr)

Karanam, G., & Arumugam, M. K. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05407-5 · Cited by 59 · see citing works

Negative regulators of cell death pathways in cancer: perspective on biomarkers and targeted therapies

Razaghi, A., Heimann, K., Schaeffer, P. M., & Gibson, S. B. (2018) · APOPTOSIS · doi:10.1007/s10495-018-1440-4 · Cited by 59 · see citing works

Multiparametric quantitative phase imaging for real-time, single cell, drug screening in breast cancer

Polanco, E. R., Moustafa, T. E., Butterfield, A., Scherer, S. D., Cortes-Sanchez, E., Bodily, T. A., Spike, B. T., Welm, B. E., Bernard, P. S., & Zangle, T. A. (2022) · Communications Biology · doi:10.1038/s42003-022-03759-1 · Cited by 56 · see citing works

Competing endogenous RNAs in lung cancer

Zhao, M., Feng, J., & Tang, L. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0203 · Cited by 59 · see citing works

Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL

Nayak, D., Lv, D., Yuan, Y., Zhang, P., Hu, W., Nayak, A., Ruben, E. A., Lv, Z., Sung, P., Hromas, R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46922-4 · Cited by 55 · see citing works

Cancer Stem Cell Hypothesis for Therapeutic Innovation in Clinical Oncology? Taking the Root Out, Not Chopping the Leaf

Dzobo, K., Senthebane, D., Rowe, A., Thomford, N., Mwapagha, L., Alawwad, N., Dandara, C., & Parker, M. (2016) · Omics · doi:10.1089/omi.2016.0152 · Cited by 59 · see citing works

Evodiamine activates cellular apoptosis through suppressing PI3K/AKT and activating MAPK in glioma

Wang, R., Deng, D., Shao, N., Xu, Y., Xue, L., Peng, Y., Liu, Y., & Zhi, F. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s155275 · Cited by 57 · see citing works

A three-dimensional bioprinted model to evaluate the effect of stiffness on neuroblastoma cell cluster dynamics and behavior

Monferrer, E., Martín-Vañó, S., Carretero, A., García‐Lizarribar, A., Burgos‐Panadero, R., Navarro, S., Samitier, J., & Noguera, R. (2020) · Scientific Reports · doi:10.1038/s41598-020-62986-w · Cited by 57 · see citing works

Chronic inflammation and long-lasting changes in the gastric mucosa after Helicobacter pylori infection involved in gastric cancer

Yang, H., Wei, B., & Hu, B. (2021) · Inflammation Research · doi:10.1007/s00011-021-01501-x · Cited by 56 · see citing works

In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models

Hughes, P. E., Rex, K. L., Caenepeel, S. R., Yang, Y., Zhang, Y., Broome, M. A., Kha, H. T., Burgess, T. L., Amore, B. M., Kaplan‐Lefko, P. J., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0871 · Cited by 56 · see citing works

The role of BCL-2 family proteins in regulating apoptosis and cancer therapy

Qian, S., Wei, Z., Yang, W., Huang, J., Yang, Y., & Wang, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.985363 · Cited by 1,011 · see citing works

Targeting BCL-2 regulated apoptosis in cancer

Campbell, K. J., & Tait, S. W. G. (2018) · Open Biology · doi:10.1098/rsob.180002 · Cited by 546 · see citing works

Biomarkers of Therapeutic Response to BCL2 Antagonists in Cancer

Lam, L. T., Zhang, H., & Chyla, B. (2012) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-012-0003-6 · Cited by 13 · see citing works

Cell Death and Targeted Cancer Therapies

(2022) · Frontiers research topics · doi:10.3389/978-2-88976-684-0

Diagnosing and exploiting cancer's addiction to blocks in apoptosis

Letai, A. G. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2297 · Cited by 577 · see citing works